MDM2 and breast cancer: The BCAC study of 5191 cases and 3834 controls found no evidence of an association of TP53 Arg72Pro and MDM2 309T>G either with breast cancer overall or with oestrogen receptor (ER) status of tumours (Schmidt et al, 2007).